Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include:

1. Mortality - All-cause mortality - Cause specific mortality - Multiple sclerosis-related mortality

2. EDSS (Expanded Disability Status Scale)

3. Cognition

4. Resource use

5. SPMS (Secondary Progressive Multiple Sclerosis) status

6. Employment history

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Previously enrolled in the Betaseron pivotal study protocols TB01-35686 in the US and TB01-35886 in Canada (total, N=372)

• Patient, caregiver, or legal guardian must provide written informed consent

• Patient must confirm her/his ability and agreement to participate in the study at the beginning of the phone call